CD44 and neoplasm: Research indicates that CD44 knockdown (CD44kd) in prostate cancer xenografts significantly reduces tumor growth rate after continuous docetaxel treatment compared with control cells, suggesting that the combination of chemotherapy with CD44kd can lead to a beneficial chemotherapy outcome (Hao et al., 2012).